A phase I trial evaluating TLT-101 for Non-Ischemic Dilated Cardiomyopathy (DCM) and Chronic Heart Failure (HF)
Latest Information Update: 23 Dec 2024
Price :
$35 *
At a glance
- Drugs TLT 101 (Primary)
- Indications Dilated cardiomyopathy
- Focus Therapeutic Use
- 23 Dec 2024 New trial record
- 11 Dec 2024 According to TikkunLev Therapeutics media release, TLT-101, is in IND-enabling development for non-ischemic DCM and HF, with an anticipated IND filing in 2025.